Body Dysmorphic DisorderNCT06781853
CBT for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial
A study testing Cognitive Behavioral Therapy (CBT) in people with Body Dysmorphic Disorder and Steroid Abuse, run by Uskudar University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this clinical trial is to evaluate the effectiveness of cognitive behavioral therapy (CBT) in treating muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid/performance-enhancing drug (PED) abuse in men aged 18-65 who regularly attend the gym. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men only
- Conditions the study is for
- Body Dysmorphic Disorder, Steroid Abuse, Body Dysmorphic Disorder (BDD), Subtype: Muscle Dysmorphia
- What is being tested?
- Cognitive Behavioral Therapy (CBT)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 71 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2024to 15 Jun 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male participants aged 18-65. Regular gym attendance (minimum three times per week). Use of steroids or performance-enhancing drugs (PEDs) for at least one year. Formal diagnosis of muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid/PED abuse, based on DSM-5-TR criteria.
- Willingness to participate in 12 weekly one-on-one online cognitive behavioral therapy (CBT) sessions.
- Ability to provide informed consent and complete assessments at baseline, post-intervention, and three-month follow-up.
Who cannot join
- Diagnoses of substance use disorders (e.g., heroin, cannabis). Diagnoses of bipolar disorder or antisocial personality disorder. Use of steroids or PEDs for medical purposes. Use of medications that could interfere with the study outcomes. Participation in any other psychotherapy or psychological intervention during the study period.
- Inability to access the internet or participate in online therapy sessions.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Üsküdar University, İstanbul, Türkiye
Istanbul, 34277
About this study
Official title: Evaluating the Effectiveness of Cognitive Behavioral Therapy for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial
The goal of this clinical trial is to evaluate the effectiveness of cognitive behavioral therapy (CBT) in treating muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid/performance-enhancing drug (PED) abuse in men aged 18-65 who regularly attend the gym. The main questions it aims to answer are:
Does CBT reduce the symptoms of muscle dysmorphia in this population? Does CBT improve psychological well-being and reduce reliance on steroids or PEDs? Researchers will compare participants receiving CBT to a control group that does not receive any intervention to determine the therapy's effectiveness.
Read more
Participants will:
Undergo a formal diagnosis of muscle dysmorphia (Under BDD) and steroid/PED abuse based on DSM-5-TR criteria through online clinical interviews.
Complete 12 weekly one-on-one online CBT sessions (50 minutes each) for those in the experimental group.
Complete psychological assessments at three time points: before the intervention, after the intervention, and at a 3-month follow-up.
This study uses validated scales to measure changes in symptoms of MD, psychological distress, and other related outcomes. The results will help determine if CBT is an effective treatment for muscle dysmorphia and associated steroid/PED abuse.
Read the detailed description
This randomized controlled trial is designed to evaluate the effectiveness of cognitive behavioral therapy (CBT) for men diagnosed with muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid or performance-enhancing drug (PED) abuse. Muscle dysmorphia is a subtype of BDD characterized by a pathological preoccupation with insufficient muscularity, often accompanied by steroid/PED use. Despite the physical and psychological risks associated with these behaviors, individuals with MD and steroid abuse rarely seek treatment due to stigma and the psychological effects of steroid use.
Study Design:
The trial will recruit male participants aged 18-65 who regularly attend the gym (at least three times per week) and have been using steroids or PEDs for at least one year. Recruitment will be conducted across 6 districts in Istanbul, targeting a diverse range of socioeconomic populations. Survey teams will approach gym-goers outside fitness clubs to introduce the study, explain its confidentiality, and emphasize the benefits of participation, including free psychiatric diagnosis and CBT sessions.
Participants will be asked to complete a sociodemographic questionnaire, and formal diagnoses of muscle dysmorphia and steroid/PED abuse will be made via online clinical interviews conducted by a psychiatrist using DSM-5-TR criteria.
Randomization and Intervention:
Participants who meet the inclusion criteria will be randomly assigned to one of two groups:
Experimental Group: Participants will receive 12 weekly one-on-one CBT sessions (50 minutes each) conducted online via Microsoft Teams. Therapy will be structured to address MD symptoms, maladaptive thought patterns, and behaviors associated with steroid/PED use.
Control Group: Participants will not receive any intervention during the study period.
Therapy sessions will be delivered by 3 side-principle investigators (authors of the study) and assistant professors in psychology who have BDD/MD and steroid abuse experinces . The therapy process will be supervised by psychiatry professor (one of the author) ensure adherence to the treatment protocol.
Outcome Measures:
Participants in both groups will be assessed at three time points: baseline (pre-intervention), post-intervention, and three-month follow-up. The following validated scales will be used:
Muscle Dysmorphic Disorder Inventory (MDDI) Patient Health Questionnaire (PHQ) Kessler Psychological Distress Scale (K10) Bodybuilder Image Grid (BIG) Eating Disorder Examination Questionnaire (EDE-Q) Exercise Addiction Inventory (EAI)
Monitoring and Supervision:
To maintain fidelity to the CBT protocol, an external monitoring committee will review recordings of therapy sessions. The committee will include two CBT-trained clinical psychologists, one clinical psychology PhD assistant professor, and one psychiatrist. Feedback will be provided to therapists to ensure consistency and adherence to the protocol.
Challenges and Mitigation:
Recognizing the stigma associated with steroid use and MD, the study incorporates strategies to build trust and encourage participation, including emphasizing confidentiality, offering free psychiatric diagnosis and therapy, and using trained survey teams to engage participants effectively. To minimize dropout rates, reminders and follow-ups will be implemented throughout the study period.
Significance:
This trial aims to address a critical gap in the treatment of muscle dysmorphia and steroid/PED abuse. By evaluating the efficacy of structured CBT delivered online, the study will provide valuable insights for developing accessible and effective interventions for this underserved and stigmatized population.
- Conditions
- Body Dysmorphic Disorder, Steroid Abuse, Body Dysmorphic Disorder (BDD), Subtype: Muscle Dysmorphia
- Being tested
- Cognitive Behavioral Therapy (CBT)
- Keywords
- Cognitive Behavioral Therapy (CBT), Muscle Dysmorphia, Body Dysmorphic Disorder (BDD), Steroid Abuse, Performance-Enhancing Drugs (PEDs)
- Medical subject headings
- Body Dysmorphic Disorders, Brachydactyly, Type D
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Behavioral Therapy (CBT)Behavioural
The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being.
| Study group | Role | What they receive |
|---|---|---|
| CBT Interventional Group | Experimental | Participants in this group will receive 12 weekly one-on-one cognitive behavioral therapy (CBT) sessions, each lasting 50 minutes, delivered online via Microsoft Teams. The intervention will target symptoms of muscle dysmorphia (MD), maladaptive thoughts, and behaviors related to steroid and performance-enhancing drug (PED) abuse. Therapy will be conducted by three assistant professors in psychology supervised by senior author psychiatrist. Receives: Behavioral: Cognitive Behavioral Therapy (CBT) |
| Control Group | No intervention | Participants in this group will not receive any intervention during the study period. They will complete the same assessments as the experimental group at baseline, post-intervention, and three-month follow-up to evaluate changes in muscle dysmorphia symptoms, psychological distress, and related behaviors for comparison. After the study, participants in this group will be offered an intensive 8-session CBT program if requested. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in Muscle Dysmorphia Symptoms
Change in muscle dysmorphia symptoms, as measured by the Muscle Dysmorphic Disorder Inventory (MDDI), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Secondary outcomes (5)
Reduction in Psychological Distress
Change in psychological distress, as measured by the Kessler Psychological Distress Scale (K10), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Improvement in General Psychological Well-being
Change in general psychological well-being, assessed using the Patient Health Questionnaire (PHQ), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Risky Body Image Behaviors
Change in risky body image behaviors, as measured by the Bodybuilder Image Grid (BIG), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Eating Disorder Symptoms
Change in eating disorder symptoms, as measured by the Eating Disorder Examination Questionnaire (EDE-Q), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Exercise Addiction Symptoms
Change in symptoms of exercise addiction, assessed using the Exercise Addiction Inventory (EAI), from baseline to post-intervention and three-month follow-up.
Measured: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2025
- Study start1 Sep 2024
- Primary completion15 Apr 2025
- Study completion15 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Body Dysmorphic DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study employs a randomized controlled trial (RCT) with a parallel assignment model to evaluate the effectiveness of cognitive behavioral therapy (CBT) for men diagnosed with muscle dysmorphia (MD) and steroid/PED abuse. Participants will be randomly assigned to an experimental group (12 weekly online CBT sessions) or a control group (no intervention). Assessments will occur at baseline, post-intervention, and three-month follow-up to measure changes in MD symptoms, psychological distress, and related behaviors. Therapists will be supervised by clinical psychologists and psychiatrists, with adherence monitored by an external committee to ensure fidelity to the CBT protocol. This design ensures a robust evaluation of the intervention's impact while addressing accessibility and stigma-related barriers.
- Masking
- None (open label)
- Enrolment
- 71 participants (actual)
Sponsor and investigators
- Lead sponsor
- Uskudar University
- Sponsor type
- University, hospital or other
- Collaborators
- Beykoz University, Istanbul Nisantasi University
- Responsible party
- Principal investigator, Selami Varol Ülker, Uskudar University
- Investigators
- Selami Varol Ülker, Phd, Principal investigator, Üsküdar UniversityMetin Çınaroğlu, Phd, Principal investigator, Istanbul Nisantasi UniversityEda Yılmazer, Phd, Principal investigator, Beykoz UniversityGokben Hızlı Sayar, Professor, Study chair, Üsküdar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06781853
- Sponsor's protocol ID
- 61351342/20-318
- Status last verified
- Jun 2025
- First submitted
- 13 Jan 2025
- Last updated
- 25 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) related to the study's primary and secondary outcome measures will be shared with other researchers upon reasonable request. The shared data will include de-identified demographic information, baseline characteristics, and assessment scores. Data will be made available following publication of the study results and can be accessed by submitting a request to the corresponding author. Requests must include a detailed research proposal and comply with all applicable ethical and legal requirements. The data will be shared in a secure format to ensure participant confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Effectiveness of Cognitive Behavioral Therapy for Muscle Dysmorphia and Steroid Abuse: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06781853
- Acronym / sponsor ID
- 61351342/20-318
- Conditions
- Body Dysmorphic Disorder, Steroid Abuse, Body Dysmorphic Disorder (BDD), Subtype: Muscle Dysmorphia
- Keywords
- Cognitive Behavioral Therapy (CBT), Muscle Dysmorphia, Body Dysmorphic Disorder (BDD), Steroid Abuse, Performance-Enhancing Drugs (PEDs)
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 71 participants (actual)
- Lead sponsor
- Uskudar UniversityUniversity, hospital or other
- Collaborators
- Beykoz University, Istanbul Nisantasi University
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 15 Apr 2025 (actual)
- Study completion
- 15 Jun 2025 (estimated)
- First posted
- 17 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the effectiveness of cognitive behavioral therapy (CBT) in treating muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid/performance-enhancing drug (PED) abuse in men aged 18-65 who regularly attend the gym. The main questions it aims to answer are:
Does CBT reduce the symptoms of muscle dysmorphia in this population? Does CBT improve psychological well-being and reduce reliance on steroids or PEDs? Researchers will compare participants receiving CBT to a control group that does not receive any intervention to determine the therapy's effectiveness.
Participants will:
Undergo a formal diagnosis of muscle dysmorphia (Under BDD) and steroid/PED abuse based on DSM-5-TR criteria through online clinical interviews.
Complete 12 weekly one-on-one online CBT sessions (50 minutes each) for those in the experimental group.
Complete psychological assessments at three time points: before the intervention, after the intervention, and at a 3-month follow-up.
This study uses validated scales to measure changes in symptoms of MD, psychological distress, and other related outcomes. The results will help determine if CBT is an effective treatment for muscle dysmorphia and associated steroid/PED abuse.
Detailed description
This randomized controlled trial is designed to evaluate the effectiveness of cognitive behavioral therapy (CBT) for men diagnosed with muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid or performance-enhancing drug (PED) abuse. Muscle dysmorphia is a subtype of BDD characterized by a pathological preoccupation with insufficient muscularity, often accompanied by steroid/PED use. Despite the physical and psychological risks associated with these behaviors, individuals with MD and steroid abuse rarely seek treatment due to stigma and the psychological effects of steroid use.
Study Design:
The trial will recruit male participants aged 18-65 who regularly attend the gym (at least three times per week) and have been using steroids or PEDs for at least one year. Recruitment will be conducted across 6 districts in Istanbul, targeting a diverse range of socioeconomic populations. Survey teams will approach gym-goers outside fitness clubs to introduce the study, explain its confidentiality, and emphasize the benefits of participation, including free psychiatric diagnosis and CBT sessions.
Participants will be asked to complete a sociodemographic questionnaire, and formal diagnoses of muscle dysmorphia and steroid/PED abuse will be made via online clinical interviews conducted by a psychiatrist using DSM-5-TR criteria.
Randomization and Intervention:
Participants who meet the inclusion criteria will be randomly assigned to one of two groups:
Experimental Group: Participants will receive 12 weekly one-on-one CBT sessions (50 minutes each) conducted online via Microsoft Teams. Therapy will be structured to address MD symptoms, maladaptive thought patterns, and behaviors associated with steroid/PED use.
Control Group: Participants will not receive any intervention during the study period.
Therapy sessions will be delivered by 3 side-principle investigators (authors of the study) and assistant professors in psychology who have BDD/MD and steroid abuse experinces . The therapy process will be supervised by psychiatry professor (one of the author) ensure adherence to the treatment protocol.
Outcome Measures:
Participants in both groups will be assessed at three time points: baseline (pre-intervention), post-intervention, and three-month follow-up. The following validated scales will be used:
Muscle Dysmorphic Disorder Inventory (MDDI) Patient Health Questionnaire (PHQ) Kessler Psychological Distress Scale (K10) Bodybuilder Image Grid (BIG) Eating Disorder Examination Questionnaire (EDE-Q) Exercise Addiction Inventory (EAI)
Monitoring and Supervision:
To maintain fidelity to the CBT protocol, an external monitoring committee will review recordings of therapy sessions. The committee will include two CBT-trained clinical psychologists, one clinical psychology PhD assistant professor, and one psychiatrist. Feedback will be provided to therapists to ensure consistency and adherence to the protocol.
Challenges and Mitigation:
Recognizing the stigma associated with steroid use and MD, the study incorporates strategies to build trust and encourage participation, including emphasizing confidentiality, offering free psychiatric diagnosis and therapy, and using trained survey teams to engage participants effectively. To minimize dropout rates, reminders and follow-ups will be implemented throughout the study period.
Significance:
This trial aims to address a critical gap in the treatment of muscle dysmorphia and steroid/PED abuse. By evaluating the efficacy of structured CBT delivered online, the study will provide valuable insights for developing accessible and effective interventions for this underserved and stigmatized population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study employs a randomized controlled trial (RCT) with a parallel assignment model to evaluate the effectiveness of cognitive behavioral therapy (CBT) for men diagnosed with muscle dysmorphia (MD) and steroid/PED abuse. Participants will be randomly assigned to an experimental group (12 weekly online CBT sessions) or a control group (no intervention). Assessments will occur at baseline, post-intervention, and three-month follow-up to measure changes in MD symptoms, psychological distress, and related behaviors. Therapists will be supervised by clinical psychologists and psychiatrists, with adherence monitored by an external committee to ensure fidelity to the CBT protocol. This design ensures a robust evaluation of the intervention's impact while addressing accessibility and stigma-related barriers.
| Arm | Type | Receives |
|---|---|---|
| CBT Interventional Group | Experimental | Behavioral: Cognitive Behavioral Therapy (CBT)Participants in this group will receive 12 weekly one-on-one cognitive behavioral therapy (CBT) sessions, each lasting 50 minutes, delivered online via Microsoft Teams. The intervention will target symptoms of muscle dysmorphia (MD), maladaptive thoughts, and behaviors related to steroid and performance-enhancing drug (PED) abuse. Therapy will be conducted by three assistant professors in psychology supervised by senior author psychiatrist. |
| Control Group | No intervention | –Participants in this group will not receive any intervention during the study period. They will complete the same assessments as the experimental group at baseline, post-intervention, and three-month follow-up to evaluate changes in muscle dysmorphia symptoms, psychological distress, and related behaviors for comparison. After the study, participants in this group will be offered an intensive 8-session CBT program if requested. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male participants aged 18-65. Regular gym attendance (minimum three times per week). Use of steroids or performance-enhancing drugs (PEDs) for at least one year. Formal diagnosis of muscle dysmorphia (MD) under body dysmorphic disorder (BDD) and steroid/PED abuse, based on DSM-5-TR criteria.
- Willingness to participate in 12 weekly one-on-one online cognitive behavioral therapy (CBT) sessions.
- Ability to provide informed consent and complete assessments at baseline, post-intervention, and three-month follow-up.
Key exclusion criteria (2 listed)
- Diagnoses of substance use disorders (e.g., heroin, cannabis). Diagnoses of bipolar disorder or antisocial personality disorder. Use of steroids or PEDs for medical purposes. Use of medications that could interfere with the study outcomes. Participation in any other psychotherapy or psychological intervention during the study period.
- Inability to access the internet or participate in online therapy sessions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Behavioral Therapy (CBT)The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being. | Behavioural | CBT Interventional Group |
Primary outcome
Reduction in Muscle Dysmorphia Symptoms
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Change in muscle dysmorphia symptoms, as measured by the Muscle Dysmorphic Disorder Inventory (MDDI), from baseline to post-intervention and three-month follow-up.
5 secondary outcomes
Reduction in Psychological Distress
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Improvement in General Psychological Well-being
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Risky Body Image Behaviors
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Eating Disorder Symptoms
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).
Reduction in Exercise Addiction Symptoms
Time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2025.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) related to the study's primary and secondary outcome measures will be shared with other researchers upon reasonable request. The shared data will include de-identified demographic information, baseline characteristics, and assessment scores. Data will be made available following publication of the study results and can be accessed by submitting a request to the corresponding author. Requests must include a detailed research proposal and comply with all applicable ethical and legal requirements. The data will be shared in a secure format to ensure participant confidentiality.
Related trials for Body Dysmorphic Disorder
Active, not recruiting
Safety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns
Body Dysmorphic Disorder, Eating Disorders
Not yet recruitingObservational study
Social Media Use and Motherhood
Postpartum Period
Not yet recruiting
Overvaluation of Weight and Shape Intervention vs The Body Project
Body Image, Mental Health Outcomes
RecruitingPhase 2
Study of Dextromethorphan in OCD and Related Disorders
Obsessive-Compulsive Disorder, Illness Anxiety Disorder
Active, not recruitingObservational study
A Multi-Dimensional Model of cAre and transItion for Patients With cOmplex RAre Diseases
Rare Diseases, Mitochondrial Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Selami Varol Ülker, Phd principal investigator
Üsküdar University
Metin Çınaroğlu, Phd principal investigator
Istanbul Nisantasi University
Eda Yılmazer, Phd principal investigator
Beykoz University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Behavioral Therapy (CBT) in people with Body Dysmorphic Disorder and Steroid Abuse, run by Uskudar University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in Muscle Dysmorphia Symptoms (time frame: Baseline, post-intervention (12 weeks), and three-month follow-up (24 weeks).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.